{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T16:09:59Z","timestamp":1773245399979,"version":"3.50.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,29]],"date-time":"2019-10-29T00:00:00Z","timestamp":1572307200000},"content-version":"vor","delay-in-days":1397,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P50 CA97274"],"award-info":[{"award-number":["P50 CA97274"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["to MG"],"award-info":[{"award-number":["to MG"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01"],"award-info":[{"award-number":["R01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA127433"],"award-info":[{"award-number":["CA127433"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["to TEW"],"award-info":[{"award-number":["to TEW"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA92153"],"award-info":[{"award-number":["R01 CA92153"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["to JRC"],"award-info":[{"award-number":["to JRC"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Predolin Foundation"},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P50 CA97274"],"award-info":[{"award-number":["P50 CA97274"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["to MG"],"award-info":[{"award-number":["to MG"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01"],"award-info":[{"award-number":["R01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA127433"],"award-info":[{"award-number":["CA127433"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["to TEW"],"award-info":[{"award-number":["to TEW"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA92153"],"award-info":[{"award-number":["R01 CA92153"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["to JRC"],"award-info":[{"award-number":["to JRC"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Predolin Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1093\/annonc\/mdv486","type":"journal-article","created":{"date-parts":[[2015,10,21]],"date-time":"2015-10-21T20:53:05Z","timestamp":1445460785000},"page":"165-172","source":"Crossref","is-referenced-by-count":34,"title":["Comprehensive serum cytokine analysis identifies IL-1RA and soluble IL-2R\u03b1 as predictors of event-free survival in T-cell lymphoma"],"prefix":"10.1016","volume":"27","author":[{"given":"M.","family":"Gupta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Stenson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"O'Byrne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.J.","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Habermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.R.","family":"Cerhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.W.","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.E.","family":"Witzig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdv486_bb0010","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv486_bb0015","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1053\/j.seminhematol.2013.11.003","article-title":"Pathology of peripheral T-cell lymphomas: where do we stand?","volume":"51","author":"Gaulard","year":"2014","journal-title":"Semin Hematol"},{"key":"10.1093\/annonc\/mdv486_bb0020","series-title":"World Health Organization Classification of Tumours","article-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"Swerdlow","year":"2008"},{"key":"10.1093\/annonc\/mdv486_bb0025","doi-asserted-by":"crossref","first-page":"e214","DOI":"10.1038\/bcj.2014.34","article-title":"The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas","volume":"4","author":"Briski","year":"2014","journal-title":"Blood Cancer J"},{"key":"10.1093\/annonc\/mdv486_bb0030","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1159\/000353778","article-title":"Autologous stem cell transplantation as the first-line treatment for peripheral T cell lymphoma: results of a comprehensive meta-analysis","volume":"131","author":"Yin","year":"2014","journal-title":"Acta Haematol"},{"key":"10.1093\/annonc\/mdv486_bb0035","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.ctrv.2014.08.001","article-title":"Therapeutic options in relapsed or refractory peripheral T-cell lymphoma","volume":"40","author":"Coiffier","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"10.1093\/annonc\/mdv486_bb0040","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1182\/blood-2012-03-419937","article-title":"Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas","volume":"120","author":"Vasmatzis","year":"2012","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdv486_bb0045","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1182\/blood-2014-04-571091","article-title":"ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes","volume":"124","author":"Parrilla Castellar","year":"2014","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdv486_bb0050","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1182\/blood-2013-11-536359","article-title":"Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma","volume":"123","author":"Iqbal","year":"2014","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdv486_bb0055","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1172\/JCI61205","article-title":"New molecular insights into peripheral T cell lymphomas","volume":"122","author":"Pileri","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1093\/annonc\/mdv486_bb0060","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1182\/blood-2014-02-555763","article-title":"Cellular origin of T-cell lymphomas","volume":"123","author":"de Leval","year":"2014","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdv486_bb0065","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.semcancer.2013.11.004","article-title":"The microenvironment in T-cell lymphomas: emerging themes","volume":"24","author":"Gaulard","year":"2014","journal-title":"Semin Cancer Biol"},{"key":"10.1093\/annonc\/mdv486_bb0070","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/ajh.23259","article-title":"Elevated pretreatment serum levels of interferon-inducible protein-10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell lymphoma patients","volume":"87","author":"Ansell","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1093\/annonc\/mdv486_bb0075","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.cyto.2012.08.028","article-title":"Pretreatment circulating serum cytokines associated with follicular and diffuse large B-cell lymphoma: a clinic-based case-control study","volume":"60","author":"Charbonneau","year":"2012","journal-title":"Cytokine"},{"key":"10.1093\/annonc\/mdv486_bb0080","doi-asserted-by":"crossref","first-page":"E223","DOI":"10.1002\/ajh.23838","article-title":"Elevated soluble IL-2Ralpha, IL-8, and MIP-1beta levels are associated with inferior outcome and are independent of MIPI score in patients with mantle cell lymphoma","volume":"89","author":"Sonbol","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1093\/annonc\/mdv486_bb0085","doi-asserted-by":"crossref","first-page":"5540","DOI":"10.1182\/blood-2011-04-351742","article-title":"Comprehensive analysis of tumor microenvironment cytokines in Waldenstrom macroglobulinemia identifies CCL5 as a novel modulator of IL-6 activity","volume":"118","author":"Elsawa","year":"2011","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdv486_bb0090","doi-asserted-by":"crossref","first-page":"6812","DOI":"10.1158\/1078-0432.CCR-13-1879","article-title":"Prognostic significance of pretreatment serum cytokines in classical Hodgkin lymphoma","volume":"19","author":"Marri","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdv486_bb0095","doi-asserted-by":"crossref","first-page":"4191","DOI":"10.1200\/JCO.2010.28.6674","article-title":"Vitamin D insufficiency and prognosis in non-Hodgkin's lymphoma","volume":"28","author":"Drake","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv486_bb0100","first-page":"95","article-title":"Design and validity of a clinic-based case-control study on the molecular epidemiology of lymphoma","volume":"2","author":"Cerhan","year":"2011","journal-title":"Int J Mol Epidemiol Genet"},{"key":"10.1093\/annonc\/mdv486_bb0105","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/ajh.21328","article-title":"Serum BLyS levels increase after rituximab as initial therapy in patients with follicular Grade 1 non-Hodgkin lymphoma","volume":"84","author":"Ansell","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1093\/annonc\/mdv486_bb0110","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1182\/blood-2011-12-396457","article-title":"Galectin-1 inhibits the viability, proliferation, and Th1 cytokine production of nonmalignant T cells in patients with leukemic cutaneous T-cell lymphoma","volume":"119","author":"Cedeno-Laurent","year":"2012","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdv486_bb0115","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1182\/blood.V85.10.2862.bloodjournal85102862","article-title":"Patterns of cytokine gene expression in peripheral T-cell lymphoma of angioimmunoblastic lymphadenopathy type","volume":"85","author":"Foss","year":"1995","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdv486_bb0120","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/0046-8177(93)90290-W","article-title":"Pathogenic significance of interleukin-6 in angioimmunoblastic lymphadenopathy-type T-cell lymphoma","volume":"24","author":"Hsu","year":"1993","journal-title":"Hum Pathol"},{"key":"10.1093\/annonc\/mdv486_bb0125","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/BF02983788","article-title":"The serum cytokine profiles of lymphoma-associated hemophagocytic syndrome: a comparative analysis of B-cell and T-cell\/natural killer cell lymphomas","volume":"77","author":"Ohno","year":"2003","journal-title":"Int J Hematol"},{"key":"10.1093\/annonc\/mdv486_bb0130","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1182\/blood-2013-12-544809","article-title":"GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features","volume":"123","author":"Wang","year":"2014","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdv486_bb0135","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1001\/archderm.1996.03890250052009","article-title":"Increased serum concentration of the soluble interleukin-2 receptor in cutaneous T-cell lymphoma. Clinical and prognostic implications","volume":"132","author":"Wasik","year":"1996","journal-title":"Arch Dermatol"},{"key":"10.1093\/annonc\/mdv486_bb0140","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0190-9622(98)70597-3","article-title":"Use of serum soluble interleukin-2 receptor levels to monitor the progression of cutaneous T-cell lymphoma","volume":"38","author":"Vonderheid","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"10.1093\/annonc\/mdv486_bb0145","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.3109\/10428194.2014.1001985","article-title":"Ultra-high level of serum soluble interleukin-2 receptor at diagnosis predicts poor outcome for angioimmunoblastic T-cell lymphoma","volume":"56","author":"Shiratori","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1093\/annonc\/mdv486_bb0150","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00432-008-0440-0","article-title":"Serum-soluble interleukin-2 receptor (sIL-2R) is an extremely strong prognostic factor for patients with peripheral T-cell lymphoma, unspecified (PTCL-U)","volume":"135","author":"Kitagawa","year":"2009","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1093\/annonc\/mdv486_bb0155","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.4161\/cbt.12.12.18144","article-title":"The role of cytokine signaling in the pathogenesis of cutaneous T-cell lymphoma","volume":"12","author":"Abraham","year":"2011","journal-title":"Cancer Biol Ther"},{"key":"10.1093\/annonc\/mdv486_bb0160","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/bmt.2014.236","article-title":"Predictive role of levels of soluble interleukin-2 receptor and C-reactive protein in selecting autologous PBSC transplantation for lymphoma","volume":"50","author":"Ariizumi","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1093\/annonc\/mdv486_bb0165","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s00277-011-1363-4","article-title":"Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens","volume":"91","author":"Goto","year":"2012","journal-title":"Ann Hematol"},{"key":"10.1093\/annonc\/mdv486_bb0170","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1111\/j.1349-7006.2012.02331.x","article-title":"SIL index, comprising stage, soluble interleukin-2 receptor, and lactate dehydrogenase, is a useful prognostic predictor in diffuse large B-cell lymphoma","volume":"103","author":"Tomita","year":"2012","journal-title":"Cancer Sci"},{"key":"10.1093\/annonc\/mdv486_bb0175","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1093\/annonc\/mdn677","article-title":"Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy","volume":"20","author":"Ennishi","year":"2009","journal-title":"Ann Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419353396?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419353396?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/27\/1\/165\/16701916\/mdv486.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T07:47:40Z","timestamp":1624693660000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419353396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["S0923753419353396"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdv486","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]}}}